EPHA5 and neuropathy: A recent study performed next generation sequencing on patients who developed significant neuropathy after paclitaxel, and identified variations of three related receptors, EPHA5/6/8, that correlated with susceptibility to paclitaxel-induced neuropathy (Apellaniz-Ruiz et al., 2017).